Stay updated on INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial
Sign up to get notified when there's something new on the INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial page.
![Latest website image capture](/pages/_next/image?url=https%3A%2F%2Fs3.us-west-2.amazonaws.com%2Fvp-files-ore%2Fresources%2F12months%2FxtSWwn27EXdyc5Vm7N7TI3gIpQs.uncropped.jpg&w=3840&q=75)
Latest updates to the INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial page
- ChecktodayNo Change Detected
- CheckyesterdayNo Change Detected
- Check2 days agoChange DetectedThe website has removed the 'Last Update Posted (Estimated)' and now features a definitive 'Last Update Posted' section.SummaryDifference0.0%
- Check4 days agoChange DetectedNew estimated update dates have been added for July 2024 and October 2025, while several previous update dates from early 2024 have been removed.SummaryDifference0.2%
- Check5 days agoChange DetectedThe study has expanded to include 179 locations, and the website has been updated to version v2.10.0, replacing the previous version v2.9.7.SummaryDifference0.1%
- Check11 days agoChange DetectedThe website has been updated to Revision v2.9.7 from v2.9.6.SummaryDifference0.0%
- Check25 days agoChange DetectedThe value of Revision has been updated from v2.9.5 to v2.9.6, indicating a recent change in the webpage content.SummaryDifference0.0%
- Check30 days agoChange DetectedThe value of Revision has been updated from v2.9.3 to v2.9.5, indicating a recent change in the version of the study record.SummaryDifference0.0%
Stay in the know with updates to INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial page.